135 related articles for article (PubMed ID: 17670914)
1. Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure.
Mistry SJ; Bank A; Atweh GF
Mol Cancer Res; 2007 Aug; 5(8):773-82. PubMed ID: 17670914
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
Miceli C; Tejada A; Castaneda A; Mistry SJ
Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Mistry SJ; Atweh GF
Mol Cancer Ther; 2006 Dec; 5(12):3248-57. PubMed ID: 17172428
[TBL] [Abstract][Full Text] [Related]
4. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle.
Iancu C; Mistry SJ; Arkin S; Atweh GF
Cancer Res; 2000 Jul; 60(13):3537-41. PubMed ID: 10910066
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Pasquier E; Honore S; Pourroy B; Jordan MA; Lehmann M; Briand C; Braguer D
Cancer Res; 2005 Mar; 65(6):2433-40. PubMed ID: 15781659
[TBL] [Abstract][Full Text] [Related]
6. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.
Mitra M; Kandalam M; Sundaram CS; Verma RS; Maheswari UK; Swaminathan S; Krishnakumar S
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5441-8. PubMed ID: 21546534
[TBL] [Abstract][Full Text] [Related]
7. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism.
Derry WB; Wilson L; Jordan MA
Cancer Res; 1998 Mar; 58(6):1177-84. PubMed ID: 9515803
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
9. Silencing Op18/stathmin by RNA Interference Promotes the Sensitivity of Nasopharyngeal Carcinoma Cells to Taxol and High-Grade Differentiation of Xenografted Tumours in Nude Mice.
Lin X; Yu T; Zhang L; Chen S; Chen X; Liao Y; Long D; Shen F
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):611-620. PubMed ID: 27289016
[TBL] [Abstract][Full Text] [Related]
10. Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy.
Dicker AP; Williams TL; Iliakis G; Grant DS
Am J Clin Oncol; 2003 Jun; 26(3):e45-53. PubMed ID: 12796615
[TBL] [Abstract][Full Text] [Related]
11. Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines.
Lin X; Liao Y; Xie J; Liu S; Su L; Zou H
Cancer Biother Radiopharm; 2014 Nov; 29(9):376-86. PubMed ID: 25379611
[TBL] [Abstract][Full Text] [Related]
12. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy.
Mistry SJ; Atweh GF
Mt Sinai J Med; 2002 Oct; 69(5):299-304. PubMed ID: 12415323
[TBL] [Abstract][Full Text] [Related]
13. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish.
Tran TC; Sneed B; Haider J; Blavo D; White A; Aiyejorun T; Baranowski TC; Rubinstein AL; Doan TN; Dingledine R; Sandberg EM
Cancer Res; 2007 Dec; 67(23):11386-92. PubMed ID: 18056466
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
Pourroy B; Honoré S; Pasquier E; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
Cancer Res; 2006 Mar; 66(6):3256-63. PubMed ID: 16540678
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antiangiogenic potential of AQ4N.
O'Rourke M; Ward C; Worthington J; McKenna J; Valentine A; Robson T; Hirst DG; McKeown SR
Clin Cancer Res; 2008 Mar; 14(5):1502-9. PubMed ID: 18316575
[TBL] [Abstract][Full Text] [Related]
17. EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.
Sun HL; Tsai AC; Pan SL; Ding Q; Yamaguchi H; Lin CN; Hung MC; Teng CM
Clin Cancer Res; 2009 Aug; 15(15):4904-14. PubMed ID: 19622586
[TBL] [Abstract][Full Text] [Related]
18. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel taxol-sensitive kinase activity associated with the cytoskeleton.
Wang Y; Duncan R; Ann DK; Hamm-Alvarez SF
Biochem Biophys Res Commun; 2000 Nov; 277(3):525-30. PubMed ID: 11061987
[TBL] [Abstract][Full Text] [Related]
20. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin.
Ng DC; Lin BH; Lim CP; Huang G; Zhang T; Poli V; Cao X
J Cell Biol; 2006 Jan; 172(2):245-57. PubMed ID: 16401721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
